The Fluo Labs offering is now closed and is no longer accepting investments.

Fluo Labs

A breakthrough in allergy symptom relief

Fluo Labs

A breakthrough in allergy symptom relief

San Marcos, CA
Consumer Products
Fluo Labs is on a mission to bring drug-free relief to the millions of people who suffer from seasonal allergies. The recent announcement of its partnership with a leading global life sciences company is energizing and will accelerate that mission to a global scale. Allergies (aka hay fever) are a trivialized condition that are often detrimental to a sufferer’s quality of life. That’s why we are pioneering science-backed light technology that will provide a new way to relieve symptoms -- without drugs. Fluo Labs is a premarket clinical stage medical device company.


Price per Share
Min. Investment
Shares Offered
Offering Type
Offering Max
Days Left


Price per Share
Min. Investment
Shares Offered
Offering Type
Offering Max
Days Left
This offering ended on October 22, 2021 and is no longer accepting investments.

Reasons to Invest

  • Own a piece of a growing global market: Over  50 Million Americans and 1 Billion more people worldwide suffer from allergies. The global allergy treatment market is set to reach  $40 billion by 2025.
  • Feel empowered by our partnership with a leading global life sciences company. Their regulatory and marketing expertise, as well as their financial support will help Fluo Labs accelerate its plans to bring innovation to the fast-growing respiratory care category on a global scale.
  • Capitalize on powerful market drivers and opportunities: 
    • Little innovation in the allergy care space leaves huge gaps of unmet consumer needs.
    • Climate change is creating longer and more intense allergy seasons.
    • Limited success of common allergy treatments for  66% of allergy sufferers
    • Consumers are rapidly shifting preferences towards non-medicated solutions. 
  • Participate in the introduction of a new category - and standard - in allergy care as we develop Fluo, our light-based technology designed to reduce allergy symptoms without medication. 


A new approach to allergy relief

We are developing an OTC medical device that uses light therapy to deliver temporary drug-free relief of allergy symptoms. Unlike traditional approaches, our technology is entirely drug-free and easy to use, working quickly to relieve the inflammation that causes allergy symptoms and ultimately improving allergy sufferers’ quality of life. 

We are preparing for our final clinical trial during the upcoming fall ragweed season. We plan to submit a De Novo petition to the FDA later in 2021.

The Problem

Seasonal allergy sufferers want better treatments

More than 50+ million Americans suffer from allergies. Of those afflicted with nasal allergies, more than 66% are dissatisfied with their current allergy medications, reporting bothersome side effects, that the medications don’t work long or fast enough, and that they don’t treat the symptoms.

* Source

Allergy symptoms can also lead to an impaired quality of life because of factors such disturbed sleep, fatigue, decline in cognitive processing, degraded memory, and depression. Overall, allergy symptoms lead to an estimated $18 billion worth of indirect costs in lost productivity and absenteeism. 

We believe the problem is only made worse by climate change, with longer and more intense allergy seasons causing prolonged suffering for more people.

Currently available allergy medications can cause unpleasant side effects:

In addition, a large number of people should not be taking allergy medications due to pre-existing conditions. 

As a result, many of today’s consumers are actively seeking alternative therapies to live less toxic lives. For those seeking non-drug solutions, there has been no single natural remedy that can provide efficient symptom relief in one convenient treatment.

The Solution

We are creating a new OTC category in allergy care

Fluo Labs is pioneering photobiomodulation, a form of light therapy, to temporarily reduce the symptoms of seasonal allergies in a drug-free manner.

Photobiomodulation is commonly used in the medical community to relieve pain, reduce inflammation, heal wounds and regenerate tissue. In the case of nasal allergies, the Fluo’s precisely engineered light structure is designed to reduce the inflammation caused by allergens, therefore reducing the miserable nasal symptoms. In this way, the device is designed to act as a natural, drug-free antihistamine. 

Our premarket clinical stage medical device is being developed as an OTC alternative to traditional allergy medications by using drug-free technology that tackles common allergy symptoms like congestion, runny nose, itchy nose and sneezing. 

Our scientists are engineering the proper therapeutic balance of wavelength, dosage, power and pulse structure to effectively contain and ultimately terminate immune and inflammatory responses and thus reduce inflammation.

The Fluo device is designed to be easy and fast to use with a treatment that takes less than 30 seconds. Here’s how our prototype currently works:


We are also launching a community marketing initiative under the Seize the Sneeze ™ banner to capture consumer insights on their personal experience with allergies. 

The Market

A novel, modern solution in a neglected space

In 2017, allergy relief is a $24 billion global market and expected to grow beyond $40 billion by 2025 with a CAGR of 6.3%.

Currently, individuals suffering from moderate allergies spend an average of $650 per year on symptom relief, even though the majority (66%) report dissatisfaction with their current allergy medications.

Yet, there has been little incentive to innovate and develop better OTC allergy treatments in the past 30 years because existing medications are considered to “do a decent job”. 

Fluo Labs is bringing a novel and modern solution to this neglected space

In what we believe is another classic tale of disruption, we are developing an entirely new category in allergy care. It’s a complete departure from the conventional allergy relief protocols. 

Our premarket clinical device is being developed as an OTC consumer product that is a drug-free alternative to antihistamines and corticosteroids

Our Traction

Patented Technology, Promising Partnerships, and More

Fluo Labs has already achieved multiple significant milestones, including:

  • Two patents granted for our innovative technology, with three additional patents filed in 2021
  • Finalist at P&G Ventures 3rd Innovation Challenge
  • Partnership with a leading global life sciences company, which will help Fluo Labs accelerate its plans to bring innovation to the fast-growing respiratory care category on a global scale. 
  • In vitro tests showing certain proteins that help control inflammatory reactions responded favorably to our dosage of light. 
  • In an IRB-sanctioned one-arm proof-of-concept study reporting a 31% improvement in the subjects’ Total Nasal Symptom Score (TNSS) over baseline, superior to what is typically found in studies for antihistamines.

* Source: Evaluating approved medications to treat allergic rhinitis in the United States: an evidence-based review of efficacy for nasal symptoms by class. Benninger M, Farrar JR, Blaiss M, Chipps B, Ferguson B, Krouse J, Marple B, Storms W, Kaliner M. Ann Allergy Asthma Immunol. 2010 Jan;104(1):13-29. 

Why Invest

Join us in building the future of allergy relief

The global allergy treatment market represents a huge market opportunity expected to hit $40 billion in 2025. 

Beyond this opportunity, we’re also on a mission to improve the quality of life of millions of allergy sufferers around the globe. Seasonal allergies aren’t going away and their symptoms increasingly cause massive physical, economic and social struggles for allergy sufferers. We see it as our duty to bring our drug-free treatment to market as soon as we can so that people with allergies can quickly get back to functioning at their best. 

We are ready to help millions of people Seize the Sneeze. Join us! 


Quick Insert

In the Press

P&G Ventures -- Press Release

P&G Ventures, the early stage startup studio within P&G (NYSE:PG), has announced the four finalists for the third annual P&G Ventures CES Innovation Challenge.

CBS This Morning

2021 CES: New products revealed at this year's all-virtual tech conference

CNET Health & Wellness

Wellness products you'll want in 2021


CNET’s Sarah Mitroff on “The most important health tech of CES 2021”. “We've seen home healthcare devices at CES for years now, but they've probably never been more important than they are this year.”

MSN News

Home health tech you need to watch in 2021


Natural, Drug-Free Allergy Solution Unveiled at CES 2021


CES 2021: Some Of The Coolest Gadgets We Saw


Our Fav New Innovative Products from CES 2021: Healthcare Tech, IoT Devices & More

Senior Planet AARP

Senior Planet “Attends” CES

Gear Diary

Fluo Labs Flo Can Tame Seasonal Allergies without Drugs? Yes, Please!


Techlicious Top Picks of CES 2021 Awards

The Garage by HP

At-home tests put health in your own hands

ICT & Health

8 radical innovations for healthcare presented at CES 2021

Offering Summary



Fluo Labs, Inc.

Corporate Address


1479 Glencrest Dr. #A, San Marcos, CA 92078

Offering Minimum



Offering Maximum



Minimum Investment Amount

(per investor)




Offering Type



Security Name


Common Stock

Minimum Number of Shares Offered



Maximum Number of Shares Offered



Price per Share



Pre-Money Valuation



Early Bird

Friends and Family – first 7 days | 10% bonus shares  

Early Bird – next 7 days | 8% bonus shares


Tier 1 perk - ($5,000+ 12% bonus shares) 

Tier 2 perk - ($10,000+ 15% bonus shares)

The 10% StartEngine Owners' Bonus

Fluo Labs, Inc. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $1.00 / share, you will receive 110 shares of Common Stock, meaning you'll own 110 shares for $100. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are cancelled or fail.

Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.

*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.

*All perks occur when the offering is completed.

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments. Salary payments made to one’s self, a friend or relative. Any expense labeled “Travel and Entertainment”. Inter company debt or back payments.

Show More
Most recent fiscal year-end:
Prior fiscal year-end:
Total Assets
$234,202.00 USD
$0.00 USD
Cash And Cash Equivalents
$1,131.00 USD
$0.00 USD
Accounts Receivable
$0.00 USD
$0.00 USD
Short Term Debt
$165,505.00 USD
$0.00 USD
Long Term Debt
$68,697.00 USD
$0.00 USD
Revenues And Sales
$0.00 USD
$0.00 USD
Costs Of Goods Sold
$0.00 USD
$0.00 USD
Taxes Paid
$800.00 USD
$0.00 USD
Net Income
-$220,043.00 USD
$0.00 USD


A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.


Fluo Labs Terminates Its Campaign on StartEngine

7 months ago

To our would-be investors and followers, 

You should have received a notice from Start Engine on October 21, 2021, informing you of our decision to terminate our equity crowdfunding campaign. The notice was sent to all investors informing them that all funds contributed for the purchase of Fluo Labs equity will be returned to you within 10 days without any holdbacks or fees.

We'd like to thank each of you for believing in the promise of our product as shown with your pledge. We would like to hear from you, and know that you have indeed been made whole with the return of your funds. For that or for any other questions, I invite you to communicate with me at

We hope you will stay in touch. Please do not hesitate to reach out at any point.

In the meanwhile, we are moving ahead with our vision of developing a technology to help allergy sufferers to alleviate their symptoms of seasonal allergies without having to use drugs.   

Only the very best to each of you,

Lawrence Johnson, CEO

Survey Says!

8 months ago

A few months ago, we sent out a survey to our dedicated community members and some helpful folks over at Surveymonkey. Why? To help us get a closer, more personal look at life with seasonal allergies is really like. And the results were eye-opening! To see what the survey-takers had to say, head here to read our breakdown of the results on our blog!


Watch our ask the allergist highlight reel!

8 months ago

We recently had a Q&A for all your allergy FAQs with Dr. Ed Lisberg, where we dug deeper into topics like dosage importance and immunotherapy side-effects, and we sure did learn a lot! If you missed the event, we’ve got some good news for you - we’ve compiled some of the most interesting questions into the short highlight reel below! Watch to learn more!

Ragweed Season is Here!

8 months ago

Ragweed: a plant in the daisy family whose small, lightweight grains of pollen can travel far and wide, or as we like to call it, a major bummer to our end-of-summer plans!

CAUTION ⚠️ Ragweed season is upon us and can last all the way through mid-October! We’ve got a while to go before our noses are in the clear!  Ragweed 🌿 season is arguably one of the most annoying times for a person with seasonal allergies. As the most common trigger for hay fever, Ragweed is sure to start trouble for a whole lot of noses out there! 🤧

To read more about Ragweed and the havoc it wreaks click here.

An inside look at the history behind Fluo Labs!

9 months ago

Believe it or not, we weren't always in the business of tackling seasonal allergies. The first chapter of our light therapy journey started when we set out to create a cosmetic application device that was intended for cosmetic use. Once that enterprise was sold, our team began pouring into the fundamental research surrounding light therapy's use for seasonal allergies. Initial studies were run with unwieldy machines operated by clinical technicians.  While the results proved to be significant in improving allergy symptoms, the technology was not ready for primetime. Our team, however, wanted to advance the technology and adapt it into a handheld device that was just as efficient and safe to use, as needed, in the comfort of one's home. In any case, our interest in this application of light therapy only got stronger when we started digging deeper into just how debilitating nasal allergies are for the 50+ million Americans who suffer from them. The more we learned, the more we realized this massive problem needed a new, better solution!

By that point, we committed to developing our technology to address the growing problem of seasonal allergies with a drug-free, effective alternative to traditional allergy meds. And getting it right was a lot harder than it sounds. Our scientists needed to research properties like wavelength, fluence, power density, pulse structure, timing, distance, coherence, beam profile, and spectral width. It's a mouthful, we know, but finding this precise balance was crucial to the effectiveness of our treatment. And after years of dedicated research, our scientists finally engineered the patented formula we have today! 

Still, there are many other complicated and time-consuming steps for us to complete. As a science-driven company, we need our technology to be both effective and trusted by consumers. To do that, we're currently taking part in extensive research and testing, acquiring patents, conducting clinical trials, and completing the complex but necessary steps of securing FDA approval. As a driven and passionate team, we've got exactly what it takes to accomplish our mission of bringing allergy relief to millions!

The story behind the Fluo device's dynamic design!

9 months ago

Last week you got to see a working prototype of our device. Getting to that stage, though, took a lot of careful planning. In today's world, design is an integral part of launching a successful product. According to this article by the Harvard Business Review, companies that employ a design strategy grow faster and have higher margins than their competitors. 


A finding that shows that superior design drives superior returns is incentive enough to dedicate efforts to the aesthetics of our device and its packaging, but for us, it was about more than just that. Beautiful and appealing designs can break the ice and help consumers introduce and adopt a new technology, which was exactly what we needed. 


We knew that our product had to be an approachable new technology - it couldn't feel mechanical or intimidating. At the same time, though, we didn't want to blend in. Instead, our product needed to stand out from other offerings in our product category. Our strategy involved using satisfying-to-hold organic shapes that are both familiar and dynamic while also being so streamlined that using the technology would be instinctively easy. We worked with Spitfire Industry, a boutique design firm that expertly straddled the delicate balance of our specific wants and needs. 


Our design strategy was crafted to gain the attention of early adopters and word-of-mouth influencers who will form the core of our early customer base. This group doesn't settle for generic design, so we are appealing to them with a strong design aesthetic. The care taken around our visual design should also reflect the care we have also taken with the quality and performance of our technology.  


We've still got some tweaking to do before our device is at its final stage (the image you see is that of a working prototype), but just looking at its bright, electric colors and dynamic shapes fills us with excitement and anticipation for how it will be received by its end users.

Announcing a partnership with a leading global life sciences company

9 months ago

We are thrilled to announce our partnership with a leading global life sciences company. The partnership champions Fluo Labs’ vision to bring its technology to a global stage. Its financial component will help Fluo Labs fulfill its mission to improve the quality of life for millions of allergy sufferers across the globe. Of even greater value is our partner’s support and leadership in regulatory, marketing and commercialization matters which will help Fluo Labs accelerate its plans to bring innovation to the fast-growing respiratory care category on a global scale. 

Please note that under our agreement, we have agreed not to identify our partner at this time as parties work diligently to establish the next phases of our partnership.

Read the announcement on GlobeNewswire.

Join us for no-nonsense answers about allergy meds on August 10th!

9 months ago

If you haven’t registered for our event already, don’t worry! There’s still time to save your spot for our chat with Dr. Lisberg on August 10th at 1 PM EST (10 AM PST). Just click the link below and you’ll get all the information you need to join us! We hope to (virtually) see you there! 

Link to join:

Fresh off the press: Fluo's device and packaging prototypes

9 months ago

Hi all!! 

We’ve just hit another fun milestone in our product development and testing phases: the working prototype of the device and the proto-packaging are done! 

As consumers, we don’t really recognize the effort that goes into product packaging, especially if said product needs to comply with FDA labeling requirements. Take the obligatory user manual for instance. It’s easy to disregard all the boring smallprint but it’s required to be in there. 

Let’s just say that there’s more to it than meets the eye and we’re proud to have created packaging that complies with regulatory obligations and still allows our brand to shine through and differentiate us from typical medical products. There is still lots of tweaking to do, but we’re quite pleased with how everything looks so far. 

The device that you see in the images below is a 3D printed working prototype which means that the device itself is functional but the design is not final. For the product packaging, the brilliant folks at Kaleidoscope produced 10 hand-assembled prototype boxes, each configured to house a device, charging cable, carrying case, quick how-to guide, a user manual and proper labeling throughout. 

These prototypes are now on their way to the Human Factors study, a necessary step towards an FDA accreditation. This study centers around how a typical user will interact with the device to ensure that the design, labeling, instructions and packaging properly explain how to effectively and safely use the device. Here are more details about the Human Factors evaluation

Stay on the lookout for updates on the subject! 😉

A Q&A for all your FAQs!

10 months ago

It’s time to get nosey! We’ve got an exclusive Ask the Allergist event on August 10th at 1 pm ET. We’ll be talking about allergy medications and debunking common assumptions about their efficacy and side effects. It’s a Q&A for all your FAQs! 

Click the link below to save your free spot! 

Botanical sexism is making seasonal allergies worse!

10 months ago

While it might not be a well-known problem, botanical sexism is just one more environmental factor that is making seasonal allergies more intense! 

How? Well, you can read about the whole history behind it here on our blog. In a nutshell, it’s because male trees make up the majority of the trees around us and they also produce A TON of pollen. With few or no female trees available to capture this pollen, there’s now a HUGE influx of this pesky allergen in our environment. Issues like “proximity pollinosis”, or allergies caused by the trees closest to you, are widespread and only getting worse. 

So, what can we do about this? Plant more female trees! Not only do they produce NO pollen (that’s right, no pollen!), they also trap pollen from male trees and turn it into their seeds (think of female trees like pollen-busting superheroes). 

But changing the way we landscape will take a long time, time that allergy-sufferers just don’t have. With climate change on the rise and no clear end to botanical sexism insight, seasonal allergies aren’t going anywhere, and in fact, are only affecting more and more people! 

Those with allergies need relief now!

Newsflash: climate change is making seasonal allergies worse!

10 months ago

In February 2021, the New York Times reported on this research, where scientists discovered that climate change is causing hay fever seasons to last longer and wreak more havoc than before! So for those of us who already dread the change of seasons, our days of suffering have just gotten longer. 

The study reported that since 1990, pollen seasons in North America have started 20 days earlier on average than they normally would, and to add insult to injury, the amount of pollen itself has increased by 21%! You can thank an increase in the release of CO2 for that! The more CO2 is released into the atmosphere, the warmer temperatures get, and when that happens, plants begin to produce and release more pollen than they usually would! 

For those of us living in Texas, The Midwest, and The Southwest, we have some more bad news to share. It just so happens that these locations are hit the hardest by climate change’s effect on hay fever. With seasonal allergies only getting worse (and with climate change progressing steadily), the need for a new way of treating bothersome symptoms is crucial!


Connect with our Seize the Sneeze™ group on Facebook!

10 months ago

We created a space where fellow allergy sufferers could unite over shared experiences with our Seize the Sneeze™ group on Facebook! Click here to join - we’ve got some exciting virtual events coming up that you won’t want to miss, starting with an exclusive Q&A with an allergist!


Funding update!

10 months ago

Wow! Within the first 10 days of our campaign, we’ve raised $50.1K all thanks to our brilliant 72 investors! We’re sending a huge enthusiastic thank you to you guys!  

Our mission of bringing allergy relief to the millions that suffer from this debilitating condition is no small thing, and we’re beyond thrilled that so many of you believe in our technology as much as we do! 

Don't forget to tell your friends about us! 

Why we chose equity crowdfunding and Startengine

11 months ago

Pre-FDA medical devices are notoriously hard to fund. We knocked on many doors and found that traditional funding channels just didn’t fit our needs. These players have little appetite for medical devices because the whole process of getting this category of product to market is a really involved and complicated one. We should know - we’ve been doing the hard work on our own for a while now! 

The next step in our complex journey involves the required and very expensive FDA and CE marking (for Europe) accreditation process.  We knew we needed to raise some serious capital to reach these crucial milestones. 

Enter the revolutionary channel of equity crowdfunding. This specific idea for funding became real and relevant in January 2021 when, at this year’s CES, we received an unexpected outpouring of messages from people asking about how they could invest in our company. That's when it became clear that using equity crowdfunding was the route we wanted to take. 

With Startengine, we’re able to raise funds for our unique technology the way we always dreamed we could -- by involving the very people we designed it for!  Thanks to new SEC regulations, SEC-certified platforms like Startengine are now empowering everyday people like you and me to invest in emerging companies. Gone are the days when startups were the exclusive domain of angel investor groups and venture capitalists.

As Howard Marks, CEO and co-founder of StartEngine, said in this piece he wrote on Medium, “These regulations regarding crowdfunding in its various forms give entrepreneurs a powerful alternate pathway to the capital they need to grow, and offer major economic reforms for investors seeking to invest in small business equity. For almost a hundred years, these kinds of investments were limited to an elite few, and now it’s finally set to benefit the people who need it most. This historic economic policy should send a clear message to all Americans: this country and all of its benefits are for everyone, regardless of race, gender, or geographic location.” 

We're drinking that Kool-Aid and we're proud to be a part of this funding revolution and to give our enthusiastic community members the chance to own a piece of our company!

Working hard to #SeizeTheSneeze!

Enlightening in-vitro test results

11 months ago

Hi all! 

We wanted to spend a bit of time today talking about something pretty exciting - the results of our in-vitro tests! 

Our team at Fluo Labs knew that using light therapy for the treatment of nasal allergies symptoms could work (and work well), but we wanted to dig deeper into our understanding of why our technology could be efficient at reducing the nagging symptoms of seasonal allergies. So, we undertook a series of studies to answer this important question and break down the specific biochemical interactions of our technology.  

In the studies, we exposed the major players of an allergic reaction (the players being human inflammatory cells and proteins) to our unique light formula and then recorded their reactions. The results of the study were enlightening! Of the many data points the study illuminated, one particularly interesting result showed that exposure to our light technology actually boosted IL-10, a potent, but natural regulator of inflammatory responses, and decreased histamine release! This suggests that exposure to our light therapy allowed the nose to have a calmer, more controlled response to allergens, giving it the power it needed to fight them off without pesky symptoms! 


While these results are preliminary and exploratory, they’re still incredibly fascinating and worked to affirm our mission to treat allergies with light. We intend to continue additional vigorous studies to keep uncovering all the ways that light therapy could prove to be a more efficient method of treatment for nasal allergies! 

Hello & thank you from Fluo Labs!

11 months ago

Hey guys!!! 

Welcome to our campaign page! We’re so thrilled to be on a platform like StartEngine to help us connect with the people that’ll bring us closer to accomplishing our ambitious, but much-needed mission of delivering relief to millions of allergy sufferers. 

Our technology is one-of-a-kind, and with your help, we’ll be able to show seasonal allergies whose boss! 

And wow!!! The response we’ve gotten from you guys so far has been incredible - we’ve already raised $9.5K! 

Thank you to everyone who’s been reaching out and especially to those who’ve already invested -welcome to the Fluo Labs team! 

Show More Updates End of Updates

Comments ({{profileCtrl.startup.comments_count}} total)

Please sign in to post a comment.
Please use Updates for communications.
{{ profileCtrl.commentsLoading ? 'Loading...' : 'Show More Comments' }}